

Alcent.

53. The method according to claim ~~43~~, wherein the two recombinant DNAs each include an identical transcriptional promoter.

54. The method according to claim ~~53~~, wherein the two recombinant DNAs are inserted in the same orientation.

55. The method according to claim ~~43~~, wherein the immuno-suppressive agent is injected both before and after injection of the adenovirus.

56. The method according to claim ~~43~~, wherein the immuno-suppressive agent and the recombinant adenovirus are injected simultaneously. --

REMARKS

Claims 1-25 have been cancelled and rewritten as new claims 26-56 in order to conform with US patent practice. In addition, new method claims 43-56 are supported at page 1, lines 3-9, page 5, lines 7-11, and page 8, lines 1-2. No new matter has been added.

Rhône-Poulenc Rorer Inc.
Legal-Patents #3C43
P.O. Box 5093
Collegeville, PA 19426-0997
Telephone: (610) 454-3839
Facsimile: (610) 454-3808

Dated: *8/14/97*

Respectfully submitted,



Paul F. Fehlner, Ph.D.
Attorney for Applicants
Registration No. 35,135